BioDelivery Sciences International Inc. (BDSI) is a company with a focus in the areas of pain management and addiction medicine.The company has 3 marketed products – Onsolis for breakthrough cancer pain, Bunavail for opioid dependence and Belbuca for chronic pain.The company’s clinical candidate is Clonidine topical gel, which is under a phase 2b study for the treatment of painful diabetic neuropathy. The preliminary results from this study are anticipated in December.BDSI is down over 63% year-to-date, and trades around $1.75.